Invitae

Invitae Financial Debt Ratio

Delisted

The Financial Debt Ratio of Invitae (NVTAQ) as of Oct 11, 2026 is 81.98 %. In the previous year, Financial Debt Ratio was 32.27 % — a change of 154.07% (higher).

Financial Debt Ratio

81.98 %

YoY

154.07%

Last updated:

Financial Debt Ratio of Invitae is 2022 81.98 % . Financial Debt Ratio of Invitae was 2021 32.27 % . It decreases by 154.07% higher compared to the previous year.

The Invitae Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2015
6.51 USD
Jan 1, 2016
10.49 USD
Jan 1, 2017
21.08 USD
Jan 1, 2018
27.50 USD
Jan 1, 2019
34.77 USD
Jan 1, 2020
11.46 USD
Jan 1, 2021
32.27 USD
Jan 1, 2022
81.98 USD
The Invitae Financial Debt Ratio history
YEARFinancial Debt RatioYoY
81.98 %+154.07%
32.27 %+181.66%
11.46 %-67.06%
34.77 %+26.48%
27.50 %+30.42%
21.08 %+101.05%
10.49 %+61.07%
6.51 %+139.54%
2.72 %—
Access this data via the Eulerpool API

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

Financial Debt Ratio of Invitae is 81.98 % in 2022.

Financial Debt Ratio of Invitae changed from 32.27 % to 81.98 %, representing a 154.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Invitae since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Invitae with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Invitae

All Key Metrics — Invitae